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Summary
We show in this study that PTEN regulates p53 protein levels and transcriptional activity through both phosphatase-
dependent and -independent mechanisms. The onset of tumor development in p53/;Pten/ mice is similar to p53/
animals, and p53 protein levels are dramatically reduced in Pten/ cells and tissues. Reintroducing wild-type or phospha-
tase-dead PTEN mutants leads to a significant increase in p53 stability. PTEN also physically associates with endogenous
p53. Finally, PTEN regulates the transcriptional activity of p53 by modulating its DNA binding activity. This study provides
a novel mechanism by which the loss of PTEN can functionally control “two” hits in the course of tumor development by
concurrently modulating p53 activity.
Introduction al., 1999). Many cancer-related mutations have been mapped
within the conserved catalytic domain of PTEN, suggesting that
PTEN (phosphatase and tensin homolog deleted on chromo- the phosphatase activity of PTEN is required for its tumor sup-
some 10) tumor suppressor gene was the first phosphatase pressor function. In addition to its phosphatase domain, PTEN
identified to be frequently mutated/deleted somatically in vari- also contains a putative C2 regulatory domain, a PIP2 binding
ous human cancers (Li et al., 1997, 1998; Steck et al., 1997). motif, two PEST homology regions, and a consensus PDZ bind-
In addition, germline mutations in the PTEN gene have been ing site. The functions of these structural domains include regu-
associated with Cowden syndrome and related diseases in lating the phosphatase activity and controlling the stability or
which patients develop hyperplastic lesions (harmatomas) in subcellular localization of PTEN (Maehama et al., 2001). Disrup-
multiple organs with increased risks of malignant transformation tion of the murine Pten locus further supports the importance
(Liaw et al., 1997; Marsh et al., 1998; Nelen et al., 1997). PTEN of PTEN as a bona fide tumor suppressor (Di Cristofano et al.,
contains a sequence motif that is highly conserved in the mem- 1998; Podsypanina et al., 1999; Suzuki et al., 1998). Homozy-
bers of the protein tyrosine phosphatase family. PTEN has been gous deletion of Pten results in early embryonic lethality. Pten
shown to possess phosphatase activity on phosphotyrosyl and heterozygous mice develop hyperplastic/neoplastic changes in
multiple organs as early as 4 weeks, with a bias toward incidencephosphothreonyl-containing substrates (Li et al., 1998; Myers
and Tonks, 1997) in vitro and on phosphatidylinositol (3,4,5) in lymphoid, endometrial, mammary, gastrointestinal, and adre-
nal gland tissues (Podsypanina et al., 1999; Suzuki et al., 1998).trisphosphate, a product of phosphatidylinositol 3-kinase
(PI3K), both in vitro and in vivo (Lee et al., 1999; Maehama and The major function of the tumor suppressor PTEN relies
on its phosphatase activity and subsequent antagonism of theDixon, 1998; Myers et al., 1998; Stambolic et al., 1998; Sun et
S I G N I F I C A N C E
It has been shown by many groups, including our own, that the major function of the PTEN tumor suppressor relies on its phosphatase
activity by antagonizing the PI3K/AKT pathway. This study provides evidence that PTEN can modulate p53 function independently
of its phosphatase activity, and that a physical interaction between PTEN and p53 is important for this modulation in vivo. We also
provide in vivo evidence for PTEN’s function inside of the nucleus. Consequently, our study provides a novel mechanism by which
PTEN regulates p53 levels and activities, and possibly provides an avenue for targeted therapy for cancers caused by PTEN or p53
loss.
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PI3K/AKT pathway (Di Cristofano and Pandolfi, 2000; Maehama tant for maintaining normal cellular functions, and disruption of
this circuit may lead to cancer formation.et al., 2001; Simpson and Parsons, 2001). Loss of PTEN func-
tion, either in murine embryonic stem cells or in human cancer
cell lines, results in accumulation of PIP3 and activation of its Results
downstream effectors, such as AKT/PKB (Franke et al., 1997;
Stambolic et al., 1998; Sun et al., 1999; Wu et al., 1998). As a PTEN and p53: A genetic study
We have generated a Pten-deficient mouse line by homologousserine/threonine protein kinase, AKT functions by phosphorylat-
ing key intermediate signaling molecules, leading to increased recombination via embryonic stem cells (ES cells). Similar to
previous reports, mice lacking PTEN died early during embryo-cell metabolism, cell growth, cell survival, and cell invasive-
ness—all hallmarks of cancer (for review, see Downward, 1998; genesis, and mice with heterozygous Pten deletion developed
tumors in various tissues (Figure 1A). However, the conse-Hanahan and Weinberg, 2000; Hill and Hemmings, 2002). Ge-
netic studies also indicate that AKT plays an essential role in quences of Pten inactivation on a 129/Balb/c genetic back-
ground are quite different from what was reported on a 129/PTEN-controlled signal transduction and tumorigenesis (Stiles
et al., 2002; Stocker et al., 2002). C57 background (R. Lesche et al., submitted). In particular,
most of the heterozygous mice are tumor free for the first sixRecent studies suggest that there is a tight link between
PTEN and p53, another major tumor suppressor. Both PTEN months of their postnatal life: 10% of Pten/ animals developed
focal lymphoid hyperplasia in the thymus and enlarged lymphand p53 regulate cell proliferation and cell death (for review,
see Bargonetti and Manfredi, 2002; Yamada and Araki, 2001). nodes near the neck and axilla (Figure 1A, left). Among aged
animals (7–14 months), 25% of them developed lymphoid hy-Even though PTEN and p53 are frequently mutated in both
inherited and spontaneous tumors in humans, concomitant mu- perplasia/dysplasia (Figure 1A, right) and 10% of those pro-
gressed to early lymphoblastic lymphoma of T cell origin, similartations in both p53 and PTEN loci are not common (Kurose et
al., 2002; Fujisawa et al., 2000; Kato et al., 2000; Koul et al., to previous reports (Podsypanina et al., 1999; Suzuki et al., 1998).
This prolonged latency in tumor development provided us2002; Rasheed et al., 1997). Several commonly used human
PTEN null tumor cell lines, such as U87 MG, 786-O, MCF-7, with a unique opportunity to genetically evaluate the possible
interaction between PTEN and p53. We generated mice hetero-and LNCap, are wild-type for p53. These genetic observations
suggest that loss of PTEN may reduce the selective pressure on zygous for both p53 and Pten (compound heterozygous,
p53/;Pten/) on the 129/Balb/c background and followed atumors during cancer progression to lose p53. Mechanistically,
several lines of evidence suggest that PTEN-controlled AKT cohort of compound heterozygous animals (n  33; male:
female  14:19) for six months. Seven p53/;Pten/ miceactivation plays an essential role in modulating MDM2-depen-
dent p53 degradation (for review, see Mayo and Donner, 2002; died between 2–6 months of age. The rest of the animals were
subjected to pathological analysis upon tumor developmentZhou and Hung, 2002). p53 is a short-lived protein and stabiliza-
tion of p53 is crucial for its tumor suppressor function. The p53 from as early as 1 month of age. As shown in Figure 1B, the
onset (left panel) and lymphoma (right panel) development inprotein is maintained at low levels in normal cells by MDM2-
mediated ubiquitination and subsequent proteolysis. AKT physi- the p53/;Pten/ mice are very similar to those of p53/ (n 
23) mice, but differ significantly from mice heterozygous for p53cally associates with MDM2 and phosphorylates MDM2 on ser-
ine residues, a key step involved in MDM2 nuclear translocation (Macleod and Jacks, 1999) and for Pten (Figure 1A). Similarly
to what was reported in p53/ animals, p53/;Pten/ miceand MDM2-mediated p53 degradation (Mayo and Donner, 2001;
Ogawara et al., 2002; Zhou et al., 2001). Therefore, it is conceiv- develop lymphomas preferentially in the lymph nodes. As shown
in Figure 1C, the enlarged lymph nodes are tightly packed withable that activation of AKT in PTEN-deficient cells may cause
more rapid p53 degradation, which could contribute to tumori- a dense population of homogeneous small lymphocytes with a
few scattered germinal centers. Immunohistochemical staininggenesis caused by PTEN loss. Furthermore, p53 can bind to
the PTEN promoter region and activate PTEN transcriptionally using anti-CD3 antibody reveals nodules of uniform, atypical,
immature T cells in the peri-follicular zones, suggesting early(Stambolic et al., 2001), although there is a debate about the
significance of such regulation (Sheng et al., 2002). lymphoblastic lymphoma of T cell origin. The majority of these
samples have well-defined cortex and medullary with someTo test the functional significance of the crosstalk between
PTEN and p53 in vivo, we employed a genetic approach to highly vascularized areas. In 40% of cases, neoplastic lympho-
cytes are packed in the vessels and have infiltrated the sur-study tumorigenesis in Pten/;p53/ compound heterozygous
mice on a 129/Balb/c genetic background. We found that the rounding tissues (data not shown).
To ensure that the initiation of tumor development inonset of lymphoma development in p53/;Pten/ mice is simi-
lar to that seen in p53/ animals. To further investigate the link p53/;Pten/ mice is not due to the loss of the second allele
of either the Pten or p53 gene (loss of heterozygosity, LOH),between PTEN and p53, we demonstrated that p53 protein
levels are dramatically reduced in Pten/ cells and that PTEN immunohistochemical (IHC) analysis was performed on the tu-
mors derived from the compound heterozygous (p53/;stabilizes p53 by increasing its half-life. Furthermore, ectopic
expression of PTEN phosphatase-dead mutants also leads to a Pten/) mice. Figure 2A shows that PTEN protein is present in
these tumors (lower left) at levels similar to adjacent normalsignificant increase in p53 protein levels, and PTEN can stabilize
p53, even in the absence of MDM2, suggesting that PTEN can tissues (lower right) and comparable to those of Pten/ mice
(upper left). However, p53 is expressed at basal levels in mostregulate p53 levels in a phosphatase-independent and MDM2-
independent manner. Significantly, we observe that PTEN physi- of the tissues and tumor samples and cannot be detected by
conventional IHC analysis (data not shown). Thus, we con-cally associates with endogenous p53, and PTEN regulates the
transcriptional activity of p53 by modulating its DNA binding. ducted PCR and Western blot analysis. The second alleles of
Pten and p53 are retained in the tumor samples (Figure 2B),Thus, PTEN-p53 may represent a self-reinforced circuit impor-
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Figure 1. Tumor development in Pten/ and
compound heterozygous p53/;Pten/ mice
A: Tumor onset curve (left panel) and spectra
(right panel) show the tumor susceptibility in
Pten/ mice on the 129/Balb/c background.
B: Tumor onset curve shows that the tumor sus-
ceptibility in p53/;Pten/ mice is greatly en-
hanced over p53 or Pten heterozygous mice but
similar to p53/ mice (left panel); the incidence
of lymphoma formation in the compound het-
erozygous animals is also similar to that of the
p53 null mice (right panel).
C: Low magnification images showing an early
lymphoblastic lymphoma in a lymph node; left,
H/E staining showing the architecture; middle,
B220-positive staining B cells; and right, CD3-posi-
tive stained T cells. Note that the central mass of
the immature cells is most positive for CD3. Bar 
200 M.
and a substantial amount of p53 protein can also be detected PTEN modulates p53 protein stability
To investigate whether PTEN indeed controls p53 function inin these tumors using an antibody that recognizes both WT and
vivo, we first measured endogenous p53 mRNA and proteinmutated form of p53 (Pab-240, Figure 2C, upper panel). To
levels in isogenic Pten/, Pten/, and Pten/ ES cells. p53ensure that WT p53 is present in the mutant sample, we con-
protein levels are significantly reduced in Pten heterozygous ESducted IP-Western blot analysis using an antibody that only
cells and almost completely lost in Pten null ES cells (Figurereacts with WT p53 (Pab-246, Figure 2C, lower panel). It ap-
3A, upper panel), while these ES cells do express similar levelspears, from this study, that WT p53 is present in the tumor
of p53 mRNA (Figure 3A, lower panel), suggesting that PTENsamples. These results lead to our conclusion that LOH is not
modulates p53 at the posttranscriptional level. To confirm that
required for the initiation of tumor development in these com- PTEN is capable of controlling p53 protein levels in vivo and to
pound heterozygous mice. However, we cannot exclude (1) loss prove that this regulation is a common mechanism rather than
of function mutations in either the p53 or Pten genes which a cell type-specific event, we measured p53 levels in brain
cannot be detected by our assay systems; (2) localized or single tissues derived from Pten conditional knockout mice (Groszer
cell-based allelic deletion or gene silencing events; and (3) that et al., 2001). Similarly to ES cell studies, p53 levels are reduced
LOH is involved in or associated with tumor progression and in heterozygous animals and almost completely lost in Pten null
brains (Figure 3B). To develop a system that is amenable tolocal invasion.
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Figure 2. The presence of PTEN and p53 in lym-
phomas generated from compound heterozy-
gous p53/;Pten/ mice
A: Immunohistochemical detection of PTEN pro-
tein. Positive signal can be detected in the brain
tissue of Pten/ heterozygous mice (upper left),
the lymphoma sample of p53/;Pten/ com-
pound heterozygous mice (lower left), the nor-
mal mammary gland adjacent to the lymphoma
seen in the lower left (lower right), but not in
the brain tissues from brain-specific Pten deletion
mice (Groszer et al., 2001).
B: PCR analysis of tail DNA and tumor DNA from
representative p53/;Pten/ compound het-
erozygous mice, indicating the presence of the
WT alleles of both p53 and Pten genes.
C: Upper panel, Western blot analysis using anti-
p53 antibody (Pab 240, Santa Cruz technology).
p53 proteins are present in the representative
tumor samples of p53/;Pten/ compound het-
erozygous mice; lower panel, cell lysate from the
tumor tissue was immunoprecipitated with an
anti-p53 antibody which specifically reacts to
the WT p53 protein (Pab 246, Santa Cruz Bio-
technology) and immunoblotted with Pab 240
antibody.
biochemical analysis, we generated several isogenic mouse em- of p53 in Ptenloxp/loxp MEF cells was significantly longer than in
Ptenloxp/loxp MEF (17 min versus 6 min, Figure 3D), providingbryonic fibroblast (MEF) lines, which are wild-type for p53 but
differ in their Pten status, first by immortalizing MEF cells from genetic evidence that PTEN controls endogenous p53 protein
levels by modulating its protein stability. Interestingly, the half-Pten conditional knockout mice (Lesche et al., 2002), Ptenloxp/loxp
(functional equivalent to WT [L/L]), and then by confirming PTEN life of p53 falls in between WT and Pten null cells (12 min) when
Ptenloxp/loxp MEF cells are pre-treated with wortmannin, a PI3and p53 expression by Northern and Western blot analyses
(data not shown). Immortalized Ptenloxp/loxp lines, which contain kinase inhibitor (see Supplemental Data at http://www.cancercell.
org/cgi/content/full/3/2/117/DC1), suggesting that PTEN mayboth p53 and PTEN protein products, were treated transiently
with Cre recombinase. Three independent clones, which carry a control p53 protein levels via both PI3 kinase/AKT-dependent
and -independent mechanisms.homozygous Pten deletion (Figure 3C, upper panel; Ptenloxp/loxp,
functional equivalent to null mutant [/]) but are wild-type for
p53, were generated and used for studies described below. PTEN affects p53 protein stability: phosphatase
and MDM2-independent mechanismsSimilar to our analysis using ES cells and brain tissues, p53
protein levels, but not mRNA levels, were significantly reduced In order to determine whether reduced p53 stability in Pten null
cells and tissues is due to a PTEN phosphatase-independentin Ptenloxp/loxp MEF cells (Figure 3C).
To determine the cause of the reduced p53 protein levels activity, we reintroduced either wild-type or PTEN phosphatase-
dead mutants into the Ptenloxp/loxp MEF cells. As shown in Figurein Pten null cells and tissues, we measured the half-life of p53
in Ptenloxp/loxp and Ptenloxp/loxp MEF cells. Notably, the half-life 4A, reintroducing WT PTEN led to a significant increase in p53
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Figure 3. PTEN controls p53 protein stability
p53 protein levels in (A) ES cells and (B) brain tissues with different Pten status, indicating that PTEN regulates p53 protein posttranscriptionally.
C: PTEN regulates p53 protein levels in isogenic MEF cell lines (upper panel). The absence of Pten gene expression and presence of p53 mRNA in Ptenloxp/loxp
MEFs are demonstrated by Northern blot analysis (lower panel).
D: PTEN controls p53 half-life. Ptenloxp/loxp and Ptenloxp/loxp MEF cells were cultured to 70% confluence before being transferred to serum free medium containing
50 g/ml cyclohexamide. Cells were directly lysed at the indicated time points and p53 proteins were detected by Western blot analysis. The half-life of
p53 protein in the presence (first row) and absence (second row) of endogenous PTEN proteins were calculated using Quantity One (Bio-Rad).
protein levels (comparing lanes 2 and 3). Interestingly, two phos- the only mechanism by which PTEN can control p53. The fact
that the PTEN phosphatase-dead mutants could regulate p53phatase-dead mutants, PTEN-CS and PTEN-GR, as well as the
PTEN-C2 domain alone, were also able to increase p53 protein levels (Figures 4A and 4B) suggests that PTEN can control p53
by multiple mechanisms, one of which does not require itslevels, even though they did not affect AKT phosphorylation, a
hallmark of PTEN’s phosphatase activity (Figure 4A, comparing phosphatase activity and thus may be MDM2 independent. To
genetically prove that PTEN can control p53 in a MDM2-inde-lane 3 with lanes 4–6). We further tested the abilities of wild–type
or PTEN-CS to modulate human p53 protein levels using p53 pendent manner, we took advantage of a p53/;Mdm2/ MEF
cell line. As illustrated in Figure 4C, the expression of PTEN lednull human osteosarcoma SAOS2 cells. Again, both the WT and
PTEN-CS mutants led to a 5- to 6-fold increase in transfected to a near 7-fold increase in p53 protein levels in the absence
of MDM2 (Figure 4C, lanes 1 and 2). Furthermore, PTEN expres-p53 protein levels but not its mRNA levels (Figure 4B). These
data suggest that (1) PTEN controls p53 protein levels in both sion could partially prevent p53 degradation caused by overex-
pression of MDM2 (Figure 4C, lanes 3 and 4). To further investi-human and murine cells; and (2) PTEN controls p53, at least in
part, by a mechanism independent of its phosphatase activity. gate the mechanism involved in MDM2-independent p53
stabilization by PTEN, we measured the half-life of p53 inThe control of p53 protein levels is orchestrated by multiple
factors with MDM2 being one of the major players. Thus, it is p53/;Mdm2/ MEF cells by transfecting p53 with and without
PTEN. The half-life of p53 is significantly prolonged in the PTENnot surprising that increased AKT activity in Pten-deficient cells
will lead to increased MDM2 phosphorylation and nuclear trans- co-transfected cells (15 hr; Figure 4D, PTEN), as compared
to p53 alone (10 hr; Figure 4D,PTEN). Again, PTEN-CS mutantlocation, resulting in p53 degradation. Similar to previous re-
ports, MDM2 nuclear translocation is indeed increased in our had similar effect on p53 protein levels (see Supplemental Data
at http://www.cancercell.org/cgi/content/full/3/2/117/DC1).Ptenloxp/loxp cells (see Supplemental Data on Cancer Cell web-
site). However, the MDM2-dependent pathway is probably not How PTEN modulates p53 half-life in the absence of MDM2
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Figure 4. PTEN controls p53 protein levels through phosphatase and MDM2-dependent and –independent mechanisms
A: Wild-type and phosphatase-dead PTEN mutants can rescue p53 protein levels in Ptenloxp/loxp MEF cells. Cell lysates were analyzed by immunoblotting
with Pab-240 p53 antibody, phospho-Akt (Ser473) antibody, and Akt antibody, respectively.
B: Co-transfection of p53 with either PTEN-WT or PTEN-CS mutant in p53 null human SAOS2 leads to increased p53 protein levels. Western blot was
immunoblotted with p53 antibody (D0-1, upper panel); lower panel, RT-PCR analysis indicates no difference in p53 mRNA levels.
C: PTEN controls p53 protein levels by an MDM2-independent mechanism. p53/;MDM2/ MEF cells were transfected with vectors expressing: p53 alone
(lane 1), p53 and PTEN (lane 2), p53 and MDM2 (lane 3), or p53/MDM2/PTEN (lane 4). Cell lysates were analyzed by immunoblotting with p53, PTEN, and
MDM2 antibodies, respectively. The Western blots were quantified (Quantity One, Bio-Rad) and the fold of increase is presented on the top of each row
as compared to the first lane.
D: PTEN controls p53s half-life by an MDM2-independent mechanism. p53/;MDM2/ MEF cells were transfected with a control or PTEN expression vector.
Twenty-four hours post transfection, the cells were transferred to serum free medium containing 50 g/ml cyclohexamide. Cells were directly lysed at the
indicated time points.
is currently unknown and is worth further investigation. Taken tate each other in vivo in the Ptenloxp/loxp cells while no PTEN/
together, the data indicate that PTEN can control p53 stability p53 complex formation could be detected in Ptenloxp/loxp cells
by both phosphatase and MDM2-dependent and -independent (Figure 5A, left panels). To determine whether PTEN, p53, and
mechanisms. MDM2 were in the same complex, we re-probed the blots with
anti-MDM2 antibody and found that MDM2 is not in the PTEN/
p53 complex (Figure 5A, upper right panel). Cell fractionationPTEN physically interacts with p53 and forms a PTEN/
studies indicate that the majority of the PTEN/p53 complex isp53 complex in the absence of MDM2
present in the nucleus (Figure 5A, lower right panel). Similarly,We then tested whether PTEN controls p53 by physically associ-
endogenous PTEN can physically associate with p53 in U2OSating with p53. Cell lysates from Ptenloxp/loxp (L/L) or Ptenloxp/loxp
(/) lines were immunoprecipitated and Western blotted with cells (Figure 5B). Using various GST fusion proteins, we further
mapped regions crucial for PTEN-p53 interaction to the car-either an anti-PTEN or an anti-p53 antibody, respectively. En-
dogenous PTEN and p53 can reciprocally co-immunoprecipi- boxy-terminal regulatory domain of p53 (R domain, amino acids
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Figure 5. Endogenous PTEN and p53 can physically form a complex in vivo
A: Left panels, PTEN and p53 reciprocally immunoprecipitate each other in the Ptenloxp/loxp WT MEF cells (first lanes), but not in Ptenloxp/loxp null MEFs (second
lanes). Since anti-PTEN antibody used here is a polyclonal antibody and PTEN migrates close to the IgG band, there is a trace amount of background
signal present in the / lane as well as IgG lane; right upper panel, Immunoblot from left panels was re-probed with MDM2 antibody and indicate that
MDM2 is not in the PTEN/p53 complex. Right lower panel shows the PTEN/p53 complex formation in the nucleus. Nuclear (N) but not cytoplasmic (C)
fractions. The cell lysates from the Ptenloxp/loxp (first two lanes) and Ptenloxp/loxp null MEFs (last two lanes) were immunoprecipitated with anti-PTEN antibody
and Western blot was probed with anti-p53 antibody. A portion of each fraction before immunoprecipitation was run on an SDS-PAGE, and resulting
Western blot was probed with anti-HDAC and anti-Actin antibodies as a controls.
B: Endogenous PTEN complexes with human p53 in U2OS cells. Untreated sub-confluent U2OS whole-cell lysates were used for immunoprecipitation (left
panel). The supernatant is shown as a control (right panel).
363–393; Figure 6A) and to the C2 domain of PTEN, which does were treated without or with leptomycin B (LMB), a nuclear
not include any part of the PTEN phosphatase domain (Fig- export inhibitor that can prevent p53 from degradation (Freed-
ure 6B). man and Levine, 1998). LMB treatment rescued p53 protein in
Ptenloxp/loxp (/) cells to a level comparable to the control cells
(Figure 7A, right panel), providing additional evidence that PTENPTEN controls the transcriptional activity of p53
controls p53 protein levels by preventing p53 from degradation.To test the functional significance of the PTEN and p53 associa-
However, LMB treatment could not restore the transcriptionaltion, we investigated whether PTEN could influence p53 tran-
activity of p53 in Ptenloxp/loxp cells (Figure 7A, left panel), indicat-scriptional activity. p53 transcriptional activity is reduced by at
ing that the physical interaction between PTEN and p53 is es-least 50% in Ptenloxp/loxp cells (Figure 7A, left panel). To separate
sential for maximizing p53s transcriptional activity. Overexpres-PTEN’s role in enhancing p53 stability from increasing p53 tran-
scriptional activity, Ptenloxp/loxp (/) and Ptenloxp/loxp (L/L) cells sion of WT PTEN in either Ptenloxp/loxp (L/L) or Ptenloxp/loxp (/)
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Figure 6. Mapping PTEN-p53 association domains
A: The WT as well as p53 N-terminal and C-terminal deletion mutants (shown in middle left panel) were in vitro translated and tested for binding to GST-
PTEN-WT (lanes 7 to 9) or GST-PTEN-CS (lanes 10 to 12).
B: The WT and PTEN deletion mutants (shown in middle right panel) were expressed as GST fusion proteins and binding of p53 was measured by incubation
with in vitro translated p53 or p53-C mutant proteins. The interaction data were quantified, relative to the 10% input shown in the first lane, for both p53
(A) and PTEN (B).
cells led to comparable increases in p53 transcriptional activity that lacks the PTEN binding domain, into p53-deficient SAOS2
cells (Figure 7C). These results suggest that the regions respon-(Figure 7B), demonstrating that the reduced p53 transcriptional
activity in Pten null cells is not due to mutations in the p53 gene. sible for the physical association between PTEN and p53 are
crucial for PTEN’s function in controlling p53 protein stability (Fig-Interestingly, expression of either PTEN-CS phosphatase-dead
mutant or the C2 domain alone, which is important for p53 ure 4A) as well as its transcriptional activity (Figures 7B and 7C).
Since PTEN controls G1-S transition and cell death throughassociation, also leads to an increase, though to a lesser extent,
of p53 transcriptional activity (Figure 7B). However, no further pathways overlapping with those controlled by p53, we are
limited by the measurable biological effects that are solely de-increase in p53 transcriptional activity could be observed when
we co-transfected WT PTEN with p53C, an active form of p53 pendent on p53 function and not influenced by PTEN status.
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Figure 7. PTEN controls p53 transcriptional activity
For comparison, luciferase activity from each experiment was normalized to that of WT cells and presented as a percentage of increase. Three independent
tests were performed for each experiment and the mean  SD was presented here.
A: p53 transcriptional activity is reduced in Ptenloxp/loxp null MEF cells. LMB treatment can restore p53 protein levels (right panel) but not its transcriptional
activity (left panel) in Ptenloxp/loxp null MEF cells. Cells were transfected with pRGCE4Luc and p53 transcriptional activity was measured 24 hr post transfection.
For LMB treatment, cells were treated with 10 M LMB for 12 hr prior to each experiment.
B: p53 transcriptional activity can be restored by reintroducing the wild-type (W), CS mutant (CS), or C2 fragment (C2) of PTEN into the Ptenloxp/loxp MEF
cells.
C: PTEN has no effects on the transcriptional activity of the C-terminal deleted p53-C, which lacks PTEN binding domain.
D: p21 transcriptional activation by the endogenous p53 in response to UV irradiation is partially impaired in Ptenloxp/loxp null MEF cells. Sub-confluent MEF
cells were irradiated with 50 J/m2 of UV. Twelve hours post irradiation, p21 mRNA levels were measured by Northern blot analysis (left panel) and the fold-
of-increase after UV treatment was quantified and presented (right panel).
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To demonstrate the biological consequence of Pten deletion trols p53 protein levels and transcriptional activity in vivo, and
PTEN exerts its role through both phosphatase-dependent andon p53 functions, we measured the endogenous p21 mRNA
levels in response to DNA damage. p21 is an immediate down- -independent mechanisms. We also provide in vivo evidence
for PTEN function inside of the nucleus, which has not beenstream target gene for p53 transcriptional activity although p21
mRNA levels can be regulated by both p53-dependent and demonstrated before.
Our initial studies rely on mice carrying mutations in the-independent mechanisms. Importantly, no literature has indi-
cated that p21 transcriptional activation in response to UV treat- endogenous gene encoding either p53 or Pten to avoid potential
side effects caused by overpression of mutant proteins in ament is controlled by the PTEN/PI3K/AKT pathway. As shown
in Figure 7D, in response to UV irradiation, p21 mRNA levels tissue culture system. We hypothesized, based on the genetic
data from p53/;Pten/ heterozygous mice, that PTEN mayare significantly increased in the WT MEFs; p53/ cells are less
responsive and p53 null cells are completely nonresponsive. control p53 protein levels. This hypothesis was confirmed by
measuring the endogenous p53 protein levels in isogenicEven though the basal mRNA level of p21 is not influenced by
Pten status, its response to UV irradiation is impaired in Pten Pten/ and Pten/ ES cells, MEF cells, and brain tissues, as
well as by measuring the half-life of p53 in the presence andnull cells (Figure 7D, right). Note the fold p21 mRNA increase in
Pten null cells falls between p53/;Pten/ and p53/;Pten/ absence of the endogenous PTEN proteins. These results pro-
vide genetic proof for PTEN’s role in controlling p53 function.cells, which fits well with the endogenous p53 function. These
results indicate that the endogenous p53 transcriptional activity Our study, together with those of others (Mayo et al., 2002;
Mayo and Donner, 2001; Ogawara et al., 2002; Zhou et al.,is indeed controlled by the PTEN tumor suppressor.
2001), may also help to explain why concomitant mutations in
both p53 and PTEN loci are not common. PTEN plays an impor-PTEN controls p53 transcription activity
by modulating its DNA binding tant role in regulating p53 protein levels and activity; loss of
PTEN may decrease the selective pressure on tumors to loseSeveral proteins have been shown to interact with the p53
C-terminal domain and enhance p53 DNA binding by relieving p53 during cancer progression.
In an attempt to further delineate the functional domainsthe C-terminal inhibitory effect (Jayaraman et al., 1997a; Nie et
al., 2000). This prompted us to measure the possible effect of responsible for PTEN-mediated p53 stabilization, we discovered
a critical role of phosphatase-independent activity of PTEN inPTEN on p53 DNA binding activity. Both WT PTEN and the
PTEN-C2 (PTEN-C) fragment markedly enhanced the DNA bind- regulating p53 protein levels and transcriptional activity. This
conclusion is based on (1) reintroduction of PTEN phosphatase-ing activity of WT p53 (Figure 8A, left panel, comparing lane 2
and lanes 3–6), similar to activation of p53 by c-Abl (lanes 14 and dead mutants as well as the PTEN-C2 region, which lack the
phosphatase domain, into Ptenloxp/loxp cells partially rescues the15). Consistent with our domain mapping studies, the PTEN-CT
domain, which has weaker binding affinity to p53 (Figure 6B), endogenous p53 protein levels (Figure 4A) and transcriptional
activity (Figure 7B); (2) PTEN increases p53 protein levels andalso has less effect on p53 DNA binding activity (lanes 7 and
8). Furthermore, PTEN had no effect on the DNA binding activity prolongs the half-life of p53 in the absence of MDM2 (Figures
4C and 4D). Since MDM2 is a key mediator for PI3K/AKT-con-of the C-terminal truncated form of p53 (p53-C), which lacks
the PTEN association domain (Figure 8A, right panel, comparing trolled p53 degradation, as suggested by previous studies, this
result indicates that PTEN can control p53 half-life indepen-lane 4 and lanes 5–7).
To show that PTEN can bind to p53 and enhance its DNA dently of PI3K/AKT/MDM2 via a currently unknown mechanism;
(3) physical interaction of PTEN and p53 is crucial for maximumbinding activity in vivo, we performed a chromatin immunopre-
cipitation analysis (ChIP) using the p21 promoter as a target. p53 transcriptional activity (Figure 7), especially for its DNA
binding activity (Figure 8).Both WT PTEN and PTEN-CS increase the binding activity of
the endogenous p53 to the p21 promoter by 2.5-fold (Figure We by no means imply that the regulation of the PI3K/
AKT pathway is not an important part of PTEN’s function in8B). To further test the significance of the PTEN-p53 interaction
on this activation, we performed the ChIP assay by co-transfect- controlling tumor formation. The fact that naturally occurring
mutations in the PTEN phosphatase domain (such as PTEN-ing PTEN with either WT p53 or p53-C mutant that is defective
in PTEN interaction (Figure 6B). Similar to their effects on the C124S and PTEN-G129E mutants) are tumor causing indicates
that the effects of PTEN’s phosphatase-independent activity inendogenous p53, WT PTEN and PTEN-CS were able to increase
the DNA binding activity of transfected p53 to the p21 promoter tumorigenesis may be more tissue specific or associated with
a more aggressive phenotype upon loss of PTEN function. How-by 2.5-fold (Figure 8C). In contrast, neither WT PTEN nor
PTEN-CS had any significant effect on the binding activity of ever, our data argue strongly that phosphatase-independent
mechanisms are important parts of PTEN’s biological functions.p53-C (Figure 8C). These data suggest that PTEN regulates
Notably, some recent studies suggest that activation of AKTp53 transcriptional activity, at least in part, by modulating its
alone, such as overexpression of a constitutively activated formDNA binding activity. This modulation depends on the physical
of AKT in transgenic mice, cannot account for all of the pheno-interaction of PTEN and p53.
types related to PTEN loss (Ackler et al., 2002; Malstrom et al.,
2001; Schwertfeger et al., 2001). In Drosophila, phenotypesDiscussion
caused by dPTEN mutation are not completely covered by
Dp110 or insulin-signaling mutants (Goberdhan et al., 1999),A major portion of the PTEN literature focuses on the function
of PTEN as a lipid phosphatase, and its antagonism of the suggesting PTEN may have a broader role than only antagoniz-
ing PIP3. Similarly, mutating the putative PIP2 motif in thePI3 kinase pathway. AKT phosphorylation/activation is generally
regarded as the hallmark for PTEN mutation. In this study, we N-terminal region of PTEN led to loss of PTEN membrane asso-
ciation and failure to rescue the PTEN null phenotype in adefine a novel role of PTEN as a tumor suppressor: PTEN con-
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Figure 8. PTEN controls p53 transcriptional activ-
ity by modulating its DNA binding activity
A: Electrophoretic mobility shift assay shows that
PTEN enhances p53 DNA binding activity. Left
panel, p53 DNA binding activity can be signifi-
cantly enhanced by wild-type PTEN (PTEN, lanes
3 and 4) and PTEN-C2 fragment (PTEN-C, lanes
5 and 6). PTEN-C2 domain with the C-terminal
tail (PTEN-CT, lanes 7 and 8) also stimulates p53
DNA binding but to a lesser extent. As a positive
control, c-Abl can significantly increase the p53
DNA binding activity (Lane 14). Right panel, DNA
binding activity of p53C, which lacks PTEN asso-
ciation domain, is not affected by the presence
of PTEN (comparing lanes 4 and 5–7).
B: ChIP analysis. Both WT PTEN and PTEN-CS acti-
vate endogenous p53 DNA binding on the p21
promoter. PCR analyses (using primers to p21)
on input DNA or -p53 immunoprecipitated DNA
are shown.
C: PTEN enhances DNA binding activity of WT
p53, but not mutated p53C in SAOS2 cells. Cells
were transfected with the plasmid combination
listed below. The DNA binding activity of p53 and
p53C on the p21 promoter was analyzed using
a ChIP assay. The fold-of-increase in the present
of PTEN was quantified and presented in the Sup-
plemental Figure S3 (see Cancer Cell website).
chemoattractive response in Dictyostelium discoideum (Iijima though we have not yet obtained any conclusive results (data
not shown). We also noted that PTEN does not affect p53-and Devreotes, 2002).
Several important issues raised by the current study are DNA complex migration significantly (Figure 8A). The PTEN-
stimulated p53-DNA complex could be supershifted by the addi-worth further investigation. First, we have defined the C2 domain
as a critical region involved in PTEN/p53 association and tion of anti-p53 antibody but not by the addition of anti-PTEN
antibody, suggesting that PTEN may not be a part of the p53-PTEN-controlled p53 function. However, since a PTEN mutant
that lacks the PTEN-C2 domain is unstable (Maehama et al., DNA complex (data not shown). Similar results were also re-
ported with other proteins, such as c-Abl (Nie et al., 2000) and2001; Simpson and Parsons, 2001), we cannot rule out that
other regions of the PTEN molecule may contribute to PTEN/p53 Ref-1 (Jayaraman et al., 1997b), which interact with the C termi-
nus of p53 and enhance p53 DNA binding. Two explanationscomplex formation. Second, it would be interesting to provide a
mechanistic explanation as to why we cannot observe the may account for this result: first, PTEN may dissociate from the
p53-DNA complex during the electrophoresis; second, PTENPTEN/p53/MDM2 triple complex in vivo (Figure 5A) or MDM2
competing with PTEN in forming complex with p53 in vitro (see may induce a conformational change of latent p53 and dissoci-
ate from p53 once bound to DNA. Nevertheless, the abilitySupplemental Figure S2 on Cancer Cell website). We hypothe-
size that the association of PTEN with the C-terminal negative- of PTEN to interact with p53 correlates well with its ability to
enhances p53 DNA binding in vitro (Figure 8A) and in vivo (Fig-regulatory domain of p53 may trigger a conformational change
in the p53 molecule, thereby preventing MDM2 binding, al- ures 8C), which supports the view that the interaction plays an
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For immunoprecipitation experiments, 500 g of cell lysate was incu-important role in p53 activation. Additionally, further in vivo
bated 12 hr at 4	C with 1 g antibody (p53 Ab-4, Oncogene Researchinvestigation is required to understand how the dynamics and
products; or PTEN antibody 9552, Cell Signaling Technology) plus 50 lstoichiometry of the PTEN/p53 complex formation are con-
Protein A agarose beads (Immobilized Protein A, Pierce). Beads were washed
trolled and altered in cancers. three times with lysis buffer and centrifuged for 5 min at 5000 g between
Similar genetic approaches have been taken by others to each wash. Protein was eluted from the beads with 50 l of 2
 Laemmli
address the potential interaction between PTEN and other tumor sample buffer (Bio-Rad). Lysates were separated on a 10% SDS-PAGE gel
and transferred onto nitrocellulose (Bio-Rad) using a Semi-Dry TransBlotsuppressor genes and oncogenes. Pten heterozygous mice
blotter (Bio-Rad).have been crossed to Ink4a/ARF (You et al., 2002) and p27 (Di
For half-life experiments, Ptenloxp/loxp cells and Ptenloxp/loxp cells wereCristofano et al., 2001) deficient mice, as well as transgenic
grown to 70% confluence and transferred to serum-free medium containing
mice expressing Wnt-1 (Li et al., 2001) or T121, a truncated SV40 50 g/ml cyclohexamide (Cyclohexamide, high purity, Calbiochem). For
T antigen which specifically inactivates the pRb family (Xiao et p53/;Mdm2 MEF cells, p53 or p53 and PTEN were transfected 24 hr prior
al., 2002). By removing one functional allele of Pten, the latencies to the addition of 50 ug/ml cyclohexamide in serum free medium. Cells were
then lysed at indicated time points and further analyzed by Western blot.of tumor formation are significantly reduced in these animals.
To evaluate the role of PI3 kinase pathway in PTEN controlled p53 proteinThese compound heterozygous mice, together with the one
levels, cells were pre-treated with 50 nM wortmannin for 10 min and thenwe have generated in this study, also provide opportunities to
proceeded to half-life study in the presence of wortmannin as describedinvestigate the interplay between different signaling pathways
above.
in tumor initiation, progression, and metastasis.
Taken together, our study provides both genetic and bio- Northern blot analysis
chemical evidence that the PTEN tumor suppressor regulates Total RNA was purified from 1 
 106 of Ptenloxp/loxp or Ptenloxp/loxp cells using
an RNeasy kit (Qiagen). Fifteen micrograms of total RNA was loaded ontothe function of p53 by both phosphatase-dependent and -inde-
a 1% agarose gel containing 5.4% formaldehyde. RNA was transferred topendent mechanisms. Our study may reveal a novel mechanism
Hybond-N nitrocellulose membrane (Amersham) and probed using stan-by which the loss of PTEN can functionally control “two” hits
dard methods. Quantitation was performed with Image Quant (Molecularin the course of tumor development by concurrently modulating
Dynamics).
PI3K and p53 activities. Thus, p53 may play an important role
in the initiation of tumorigenesis by mutations in the PTEN tumor Immunohistochemistry
suppressor gene, and therapies designed to target both PTEN Immunohistochemical analysis was performed on formalin-fixed paraffin
sections following antigen retrieval (BioGenex). PTEN antibody (26H9, Celland p53 or their controlled pathways may be beneficial for those
Signaling Technology), VECTASTAIN ABC Kit (Mouse IgG, 1:200, Vectorcancers genetically marked as PTEN null and p53 WT.
Laboratories), and AEC (3-amino-9-ethylcarbazole) substrate (BioGenex)
were used for detection according to the recommended protocol.Experimental procedures
Transcriptional activation assayImmortalization of MEF cells
The transcriptional activity of p53 was measured using pRGCE4Luc whichPrimary MEF cells were harvested from embryonic day 14 embryos with
contains one copy of the RGC p53 binding site cloned upstream of theindicated genotype. Independent immortalized MEF lines were established
adenovirus E4 TATA box and luciferase gene. Cells were lysed 24 hr postusing the 3T9 protocol (Kamijo et al., 1997). To derive Ptenloxp/loxp (/) cells,
transfection in passive lysis buffer in accordance with the Dual-Glo Lucifer-immortalized Ptenloxp/loxp (L/L) cells, which were positive for Pten and p53
ase Assay System (Promega). Samples were normalized using Renilla Lucif-expressions, were transiently transfected with pTurbo-Cre (ES Cell Center,
erase. Cells treated with LMB (10 M) were lysed 12 hr post LMB addition.Washington University, St Louis, Missouri) using Effectene transfection re-
agent (Qiagen) following recommended protocols. Individual colonies were
Electrophoretic mobility shift assay (EMSA)expanded and tested for Pten deletion by both PCR and Western blot
EMSA was carried out as described (Nie et al., 2000). Briefly, the RGC p53analysis (Lesche et al., 2002), and approximately 30% of these clones had
binding site probe (5-AGCTTGCCTCGAGCTTGCCTGGACTTGCCTGGTthe exon 5 of the Pten gene deleted.
CGACGC-3) was 32P-labeled with the Klenow fragment. Binding reactions
contained 200 cpm of 32P-labeled probe, 75 ng of wild-type p53, or 10 ngCell culture and transfection
of p53C (363), in the presence of 50 or 100 ng of GST-PTEN, GST-MEF and SAOS2 cells were cultured in Dulbecco’s modified Eagle’s medium
PTEN-C, GST-PTEN-CT, GST, or GST-c-Abl, in a total volume of 12.5 l of(DMEM Gibco) supplemented with 10% fetal calf serum (FCS Hyclone), 100
reaction buffer (60 mM KCl, 12% glycerol, 5 mM MgCl2, 1 mM EDTA, 1 gU/ml penicillin and streptomycin (Gibco). To reintroduce PTEN-WT, CS, and
BSA, 0.1 g poly [d(GC)]). Reactions were incubated at 30	C for 30 min,GR mutants, or PTEN-C2 domain into Pten/ cells, the above plasmids were
and then analyzed on a 5% polyacrylamide gel containing 0.5 
 TBE (0.045cotransfected with a CMV-EGFP vector. GFP-positive cells were then FACS
mM Tris-borate, 0.045 mM sodium borate, 0.001 mM EDTA [pH 8.0]). DNA-sorted and analyzed as described. U2OS cells were cultured in McMoy’s
protein complexes were visualized with a PhosphorImager using Adobe5A supplemented with 10% FCS. Cell transfection was performed using
Photoshop software.lipofectAMINE (Invitrogen) or calcium phosphate method. Cells were lysed
28 hr post transfection for protein and luciferase activity measurements.
GST pulldown assay
The p53 N-terminal and C-terminal deletion mutants were synthesized ac-Western blot analysis and immunoprecipitation
Whole-cell extract was prepared by lysing the cells in a buffer containing 50 cording to conditions recommended by the manufacturer (Promega). The
mRNAs were translated in vitro for 1.5 hr at 30	C in rabbit reticulocytemM Tris-HCl (pH 8.0), 120 mM NaCl, 0.5% NP-40, 0.25% Na Deoxycholate, 1
mM DTT, 2 g/ml aprotinin, and 2 g/ml leupeptin. Brain tissue was dis- lysate in the presence of 35S-methionine. Bacterially expressed GST-PTEN
or PTEN-CS was incubated for 60 min with Glutathione-Sepharose (Phar-rupted using a Sonic Dismembrator in buffer containing 50 mM Tris-HCl (pH
8.0), 120 mM NaCl, 0.5% NP-40, 0.25% Na Deoxycholate, 1 mM DTT, 2 macia) in lysis buffer (20 mM Tris-borate [pH 8.0], 150 mM NaCl, 1% Triton
X-100, 10% Glycerol, 2 mM EDTA, 2 mM DTT, 2 g/ml Aproptinin, 2 g/mlg/ml aprotinin, and 2 g/ml leupeptin. Cell lysates from each transfection
were subjected to SDS-PAGE followed by Western blot analysis using anti- Leupeptin. 0.5 mM PMSF). Beads were then incubated for 60 min with the
35S-methionine labeled p53 mutants in incubation buffer (20 mM HEPES [pHp53 (DO.1, Pab-240, Santa Cruz, FL-393-G, Santa Cruz), PTEN (9552, Cell
Signaling Technologies), MDM2 (SMp14, Santa Cruz, Ab-2, Oncogene Re- 7.4], 150 mM KCl, 0.1% Triton X-100, 10% Glycerol, 0.1 mg/ml BSA, 5 mM
EDTA, 5 mM DTT, 4 g/ml Aproptinin, 4 g/ml Leupeptin, 1 mM PMSF)search Products), or Vinculin (VIN-11-5, Sigma) or Actin (A 4700, Sigma)
antibodies, respectively. with constant mixing. After incubation, the beads were washed three times
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Fujisawa, H., Reis, R.M., Nakamura, M., Colella, S., Yonekawa, Y., Kleihues,with incubation buffer and boiled in 15 l of 2
 SDS sample buffer. The
P., and Ohgaki, H. (2000). Loss of heterozygosity on chromosome 10 isbound proteins were analyzed by SDS-PAGE and 35S-labeled proteins were
more extensive in primary (de novo) than in secondary glioblastomas. Lab.visualized by autoradiography. The PTEN deletion mutants were constructed
Invest. 80, 65–72.by PCR amplification and expressed as GST fusion proteins. Binding to p53
was measured by incubation with in vitro translated p53 or p53-C363 in Goberdhan, D.C., Paricio, N., Goodman, E.C., Mlodzik, M., and Wilson, C.
the conditions as described above. (1999). Drosophila tumor suppressor PTEN controls cell size and number
by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev. 13,
Chromatin-immunoprecipitation (ChIP) analysis 3244–3258.
ChIP analysis was carried out as described (Ma et al., 2001), except that the
Groszer, M., Erickson, R., Scripture-Adams, D.D., Lesche, R., Trumpp, A.,anti-p53 (FL-393-G, Santa Cruz) antibody was used for immunoprecipitation.
Zack, J.A., Kornblum, H.I., Liu, X., and Wu, H. (2001). Negative regulationAfter reversing the formaldehyde crosslinking by heating at 65	C overnight,
of neural stem/progenitor cell proliferation by the Pten tumor suppressorDNA was extracted with phenol/chloroform, precipitated with ethanol, and
gene in vivo. Science 294, 2186–2189.dissolved in a total of 50 l TE buffer. PCR amplifications were performed
with 2 l of DNA, using 25 and 30 cycles for SAOS2 and U2OS cells, Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100,
respectively. Primers used in PCR were 5-GTGGCTCTGATTGGCTTTCTG- 57–70.
3 (forward) and 5-CTGAAAACAGGCAGCCCAAG-3 (reverse). PCR prod-
Hill, M., and Hemmings, B. (2002). Inhibition of protein kinase B/Akt. Implica-ucts were resolved by agarose-gel electrophoresis and visualized by ethid-
tions for cancer therapy. Pharmacol. Ther. 93, 243–251.ium bromide staining.
The amounts of plasmids transfected into U2OS cells by lipofectAMINE Iijima, M., and Devreotes, P. (2002). Tumor suppressor PTEN mediates sens-
(Invitrogen) were as follows: 4 g of pMX-IES-gfp-PTEN, 4 g of pMX-IES- ing of chemoattractant gradients. Cell 109, 599–610.
gfp-PTEN-CS. The amounts of plasmids transfected into SAOS2 cells by
Jayaraman, L., Freulich, E., and Prives, C. (1997a). Functional dissection ofEffectene (Qiagen) were as follows: 0.4 g of pCDNA-p53, 0.4 g of pCDNA-
p53 tumor suppressor protein. Methods Enzymol. 283, 245–256.p53C, 2 g of p21p (a gift from Dr. Xiao-Fan Wang), 4 g of pMX-IES-
gfp-PTEN, 4 g of pMX-IES-gfp-PTEN-CS. Jayaraman, L., Murthy, K.G., Zhu, C., Curran, T., Xanthoudakis, S., and
Prives, C. (1997b). Identification of redox/repair protein Ref-1as a potent
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